Akorn Current Ratio 2006-2018 | AKRX

Akorn current ratio from 2006 to 2018. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Akorn Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2018-09-30 $0.67B $0.19B 3.47
2018-06-30 $0.70B $0.18B 3.94
2018-03-31 $0.71B $0.15B 4.64
2017-12-31 $0.73B $0.17B 4.27
2017-09-30 $0.76B $0.18B 4.16
2017-06-30 $0.70B $0.13B 5.46
2017-03-31 $0.74B $0.18B 4.21
2016-12-31 $0.69B $0.18B 3.91
2016-09-30 $0.64B $0.16B 4.14
2016-06-30 $0.59B $0.14B 4.28
2016-03-31 $0.53B $0.20B 2.72
2015-12-31 $0.71B $0.23B 3.06
2015-09-30 $0.70B $0.24B 2.94
2015-06-30 $0.61B $0.20B 3.05
2015-03-31 $0.54B $0.15B 3.54
2014-12-31 $0.48B $0.15B 3.16
2014-09-30 $0.49B $0.13B 3.69
2014-06-30 $0.40B $0.10B 3.83
2014-03-31 $0.19B $0.08B 2.44
2013-12-31 $0.17B $0.06B 2.76
2013-09-30 $0.21B $0.05B 4.60
2013-06-30 $0.19B $0.04B 4.73
2013-03-31 $0.17B $0.04B 4.14
2012-12-31 $0.16B $0.04B 3.67
2012-09-30 $0.14B $0.04B 3.65
2012-06-30 $0.12B $0.03B 4.10
2012-03-31 $0.11B $0.03B 3.61
2011-12-31 $0.16B $0.03B 5.51
2011-09-30 $0.19B $0.02B 9.05
2011-06-30 $0.18B $0.02B 9.96
2011-03-31 $0.08B $0.02B 3.66
2010-12-31 $0.07B $0.02B 3.36
2010-09-30 $0.04B $0.01B 3.80
2010-06-30 $0.03B $0.01B 3.79
2010-03-31 $0.03B $0.02B 1.66
2009-12-31 $0.03B $0.02B 1.20
2009-09-30 $0.03B $0.03B 1.23
2009-06-30 $0.04B $0.03B 1.27
2009-03-31 $0.05B $0.03B 1.54
2008-12-31 $0.04B $0.02B 2.25
2008-09-30 $0.05B $0.03B 1.85
2008-06-30 $0.04B $0.02B 1.96
2008-03-31 $0.05B $0.02B 2.02
2007-12-31 $0.05B $0.02B 2.18
2007-09-30 $0.04B $0.02B 2.44
2007-06-30 $0.03B $0.01B 5.12
2007-03-31 $0.04B $0.01B 4.10
2006-12-31 $0.04B $0.01B 3.87
2006-09-30 $0.04B $0.01B 6.61
2006-06-30 $0.04B $0.01B 6.65
2006-03-31 $0.04B $0.01B 4.62
2005-12-31 $0.02B $0.02B 1.02
2005-09-30 $0.02B $0.01B 2.30
2005-06-30 $0.02B $0.01B 2.24
2005-03-31 $0.02B $0.01B 2.36
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.558B $0.841B
Akorn, Inc. is a specialty generic pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals. They specialize in difficult-to-manufacture sterile and non-sterile dosage forms including: ophthalmics, injectables, oral liquids, otics, topicals, inhalants, and nasal sprays. Akorn markets its products to retail pharmacies, ophthalmologists, optometrists, physicians, veterinarians, hospitals, clinics, wholesalers, distributors, group purchasing organizations, and government agencies. Their strategy is focused on continuing to strengthen our leadership position in the development and marketing of specialized generic and branded pharmaceuticals, over-the-counter (`OTC`) drug products and animal health products.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $45.888B 8.26
Teva Pharmaceutical Industries (TEVA) Israel $18.324B 6.32
Mylan (MYL) United Kingdom $16.552B 6.82
Bausch Health Cos (BHC) Canada $8.810B 6.38
Dr Reddy's Laboratories (RDY) India $6.044B 24.11
Supernus Pharmaceuticals (SUPN) United States $1.990B 18.86
Mallinckrodt Public Limited Company (MNK) United Kingdom $1.827B 3.05
Amphastar Pharmaceuticals (AMPH) United States $1.121B 121.55
Homology Medicines (FIXX) United States $0.901B 0.00
CymaBay Therapeutics (CBAY) United States $0.612B 0.00
Assembly Biosciences (ASMB) United States $0.573B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.402B 0.00
Voyager Therapeutics (VYGR) United States $0.351B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.292B 0.00
Sol-Gel Technologies (SLGL) Israel $0.123B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.089B 0.00
Teligent (TLGT) United States $0.087B 0.00
Acasti Pharma (ACST) Canada $0.072B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.062B 0.00
Evoke Pharma (EVOK) United States $0.056B 0.00
Agile Therapeutics (AGRX) United States $0.035B 0.00
Aevi Genomic Medicine (GNMX) United States $0.014B 0.00
China Pharma Holdings (CPHI) China $0.012B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.005B 0.00